Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 650

1.

High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.

Shah NB, Mitchell RE, Proctor ST, Choi L, DeClercq J, Jolly JA, Hemnes AR, Zuckerman AD.

PLoS One. 2019 Jun 6;14(6):e0217798. doi: 10.1371/journal.pone.0217798. eCollection 2019.

2.

Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.

Reynolds VW, Chinn ME, Jolly JA, Kelley TN, Peter ME, Choi L, Nwosu S, Leon BC, Zuckerman AD.

J Clin Lipidol. 2019 Mar - Apr;13(2):254-264. doi: 10.1016/j.jacl.2019.01.003. Epub 2019 Jan 14.

PMID:
30745204
3.

Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.

Banks AM, Peter ME, Holder GM, Jolly JA, Markley BM, Zuckerman SL, Choi L, Nwosu S, Zuckerman AD.

J Pharm Pract. 2019 Jan 30:897190018824821. doi: 10.1177/0897190018824821. [Epub ahead of print]

PMID:
30700202
4.

Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes.

Zuckerman A, Carver A, Chastain CA.

Curr Treat Options Infect Dis. 2018;10(4):431-446. doi: 10.1007/s40506-018-0177-5. Epub 2018 Oct 18. Review.

5.

Role of Endogenous and Exogenous Corticosterone on Behavioral and Cognitive Responses to Low-Pressure Blast Wave Exposure.

Zuckerman A, Ram O, Ifergane G, Matar MA, Kaplan Z, Hoffman JR, Sadot O, Cohen H.

J Neurotrauma. 2019 Jan 15;36(2):380-394. doi: 10.1089/neu.2018.5672. Epub 2018 Sep 5.

PMID:
29947272
6.

Lactobacillus rhamnosus GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells.

Riehl TE, Alvarado D, Ee X, Zuckerman A, Foster L, Kapoor V, Thotala D, Ciorba MA, Stenson WF.

Gut. 2019 Jun;68(6):1003-1013. doi: 10.1136/gutjnl-2018-316226. Epub 2018 Jun 22.

PMID:
29934438
7.

Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.

Zuckerman A, Douglas A, Nwosu S, Choi L, Chastain C.

PLoS One. 2018 Jun 18;13(6):e0199174. doi: 10.1371/journal.pone.0199174. eCollection 2018.

8.

Retreatment Options Following HCV Direct Acting Antiviral Failure.

Zuckerman A, Chastain CA, Naggie S.

Curr Treat Options Infect Dis. 2017 Dec;9(4):389-402. doi: 10.1007/s40506-017-0136-6. Epub 2017 Nov 4.

9.

Opioid Prescription and Patient Use After Gynecologic Procedures: A Survey of Patients and Providers.

Griffith KC, Clark NV, Zuckerman AL, Ferzandi TR, Wright KN.

J Minim Invasive Gynecol. 2018 May - Jun;25(4):684-688. doi: 10.1016/j.jmig.2017.11.005. Epub 2017 Nov 14.

PMID:
29154933
10.

Transition of care to an adult provider.

Zuckerman AL.

Curr Opin Obstet Gynecol. 2017 Oct;29(5):295-300. doi: 10.1097/GCO.0000000000000401. Review.

PMID:
28834787
11.

Medical Students Leading Quality Improvement: A Lean Six Sigma Approach to Pain Management.

Droullard D, Porter S, Zuckerman A, Monie D, Brendle J, Weil H.

Am J Med Qual. 2017 Sep/Oct;32(5):569. doi: 10.1177/1062860617714137. Epub 2017 Jun 21. No abstract available.

PMID:
28635297
12.

Behavioral and inflammatory response in animals exposed to a low-pressure blast wave and supplemented with β-alanine.

Hoffman JR, Zuckerman A, Ram O, Sadot O, Stout JR, Ostfeld I, Cohen H.

Amino Acids. 2017 May;49(5):871-886. doi: 10.1007/s00726-017-2383-8. Epub 2017 Feb 4.

13.

Clinical Recommendation: Vulvovaginitis.

Zuckerman A, Romano M.

J Pediatr Adolesc Gynecol. 2016 Dec;29(6):673-679. doi: 10.1016/j.jpag.2016.08.002. Epub 2016 Sep 21. Review.

PMID:
27969009
14.

See, Test & Treat: A 5-Year Experience of Pathologists Driving Cervical and Breast Cancer Screening to Underserved and Underinsured Populations.

Magnani B, Harubin B, Katz JF, Zuckerman AL, Strohsnitter WC.

Arch Pathol Lab Med. 2016 Dec;140(12):1411-1422. Review.

PMID:
27922769
15.

Ambulatory Electronic Health Records Must Be More Interoperable to Support Optimal Practice.

Zuckerman AE.

J Ambul Care Manage. 2017 Jan/Mar;40(1):6-8. No abstract available.

PMID:
27902547
16.

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.

Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, Geier J, Kwok K, Riese R.

Semin Arthritis Rheum. 2016 Dec;46(3):261-271. doi: 10.1016/j.semarthrit.2016.05.014. Epub 2016 Jun 2.

17.

A framework for assessing outcomes from newborn screening: on the road to measuring its promise.

Hinton CF, Homer CJ, Thompson AA, Williams A, Hassell KL, Feuchtbaum L, Berry SA, Comeau AM, Therrell BL, Brower A, Harris KB, Brown C, Monaco J, Ostrander RJ, Zuckerman AE, Kaye C, Dougherty D, Greene C, Green NS; Follow-up and Treatment Sub-committee of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC).

Mol Genet Metab. 2016 Aug;118(4):221-9. doi: 10.1016/j.ymgme.2016.05.017. Epub 2016 May 31.

18.

Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.

Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R.

Semin Arthritis Rheum. 2016 Aug;46(1):71-80. doi: 10.1016/j.semarthrit.2016.03.004. Epub 2016 Mar 9. Review.

19.

The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.

Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, Billaud EM, Chambers D, Danziger-Isakov L, Fedson S, Gould K, Gregson A, Grossi P, Hadjiliadis D, Hopkins P, Luong ML, Marriott DJE, Monforte V, Muñoz P, Pasqualotto AC, Roman A, Silveira FP, Teuteberg J, Weigt S, Zaas AK, Zuckerman A, Morrissey O.

J Heart Lung Transplant. 2016 Mar;35(3):261-282. doi: 10.1016/j.healun.2016.01.007. Epub 2016 Jan 19. No abstract available.

PMID:
26970469
20.

Controlled Low-Pressure Blast-Wave Exposure Causes Distinct Behavioral and Morphological Responses Modelling Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder, and Comorbid Mild Traumatic Brain Injury-Post-Traumatic Stress Disorder.

Zuckerman A, Ram O, Ifergane G, Matar MA, Sagi R, Ostfeld I, Hoffman JR, Kaplan Z, Sadot O, Cohen H.

J Neurotrauma. 2017 Jan 1;34(1):145-164. doi: 10.1089/neu.2015.4310. Epub 2016 Mar 30.

PMID:
26885687
21.

Engraftment of enteric neural progenitor cells into the injured adult brain.

Belkind-Gerson J, Hotta R, Whalen M, Nayyar N, Nagy N, Cheng L, Zuckerman A, Goldstein AM, Dietrich J.

BMC Neurosci. 2016 Jan 25;17:5. doi: 10.1186/s12868-016-0238-y.

22.

The Scale Imperative for Academic Medical Centers: Part 1--Approach.

Zuckerman AM, Golden RN.

J Healthc Manag. 2015 Jan-Feb;60(1):8-13. No abstract available.

PMID:
26529987
23.

The Scale Imperative for Academic Medical Centers: Part 2--Case Study.

Zuckerman AM, Golden RN.

J Healthc Manag. 2015 Mar-Apr;60(2):86-90. No abstract available.

PMID:
26529844
24.

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li H, Schulman SL, Raber S, Zuckerman A, Isaacs JD.

Arthritis Res Ther. 2015 Apr 6;17:95. doi: 10.1186/s13075-015-0612-7.

25.

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.

Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB.

Arthritis Rheumatol. 2015 Mar;67(3):616-25. doi: 10.1002/art.38974.

26.

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.

Isaacs JD, Zuckerman A, Krishnaswami S, Nduaka C, Lan S, Hutmacher MM, Boy MG, Kowalski K, Menon S, Riese R.

Arthritis Res Ther. 2014 Jul 25;16(4):R158. doi: 10.1186/ar4673.

27.

Successful strategic planning for a reformed delivery system.

Zuckerman AM.

J Healthc Manag. 2014 May-Jun;59(3):168-72. No abstract available.

PMID:
24988670
28.

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.

McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, Luo Z, Brosnan MJ, Zuckerman A, Zwillich SH, Bradley JD.

Ann Rheum Dis. 2014 Jan;73(1):124-31. doi: 10.1136/annrheumdis-2012-202442. Epub 2013 Mar 12.

PMID:
23482473
29.

What would you do? How do we accelerate the growth of primary care?

Zuckerman AM.

Healthc Financ Manage. 2012 Dec;66(12):108-9. No abstract available.

PMID:
23252238
30.

What would you do? Is independence the right strategy?

Zuckerman AM.

Healthc Financ Manage. 2012 Oct;66(10):120, 122. No abstract available.

PMID:
23088065
31.

What would you do? Which initiatives should a health system pursue in a highly competitive market?

Zuckerman AM.

Healthc Financ Manage. 2012 Aug;66(8):134-6. No abstract available.

PMID:
22931037
32.

What would you do? What should our new system's strategic priorities be post-merger?

Zuckerman AM.

Healthc Financ Manage. 2012 May;66(5):144-6. No abstract available.

PMID:
22616519
33.

What would you do? Which system is the best target for a close affiliation?

Zuckerman AM.

Healthc Financ Manage. 2012 Feb;66(2):104-5. No abstract available.

PMID:
22372301
34.

What would you do? What should our strategy be in the post-reform era?

Zuckerman AM.

Healthc Financ Manage. 2011 Dec;65(12):118, 120. No abstract available.

PMID:
22292336
35.

Carry on: spontaneous object carrying in 13-month-old crawling and walking infants.

Karasik LB, Adolph KE, Tamis-LeMonda CS, Zuckerman AL.

Dev Psychol. 2012 Mar;48(2):389-97. doi: 10.1037/a0026040. Epub 2011 Nov 14.

36.

What would you do? Is a merger the answer?

Zuckerman AM.

Healthc Financ Manage. 2011 Oct;65(10):124-6. No abstract available.

PMID:
22053653
37.

How should the medical staff and hospital be aligned in a post-reform market?

Zuckerman AM.

Healthc Financ Manage. 2011 Aug;65(8):134-5. No abstract available.

PMID:
21866730
38.

Healthcare mergers and acquisitions: strategies for consolidation.

Zuckerman AM.

Front Health Serv Manage. 2011 Summer;27(4):3-12; discussion 39-41.

PMID:
21793480
39.

What would you do? How do we develop the scale and scope needed for the future?

Zuckerman AM.

Healthc Financ Manage. 2011 Jun;65(6):132, 134. No abstract available.

PMID:
21692386
40.

What would you do? Should we develop a children's hospital?

Zuckerman AM.

Healthc Financ Manage. 2011 Apr;65(4):128-30. No abstract available.

PMID:
21548439
41.

Does the strategic plan require updating because of healthcare reform?

Zuckerman AM.

Healthc Financ Manage. 2011 Feb;65(2):102, 104. No abstract available.

PMID:
21428231
42.

Hepatitis Viruses.

Zuckerman AJ.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 70.

43.

Standardizing newborn screening results for health information exchange.

Abhyankar S, Lloyd-Puryear MA, Goodwin R, Copeland S, Eichwald J, Therrell BL, Zuckerman A, Downing G, McDonald CJ.

AMIA Annu Symp Proc. 2010 Nov 13;2010:1-5.

44.

Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative.

Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, Baker LA, Baratz AB, Baskin LS, Berenbaum SA, Breault DT, Cerame BI, Conway GS, Eugster EA, Fracassa S, Gearhart JP, Geffner ME, Harris KB, Hurwitz RS, Katz AL, Kalro BN, Lee PA, Alger Lin G, Loechner KJ, Marshall I, Merke DP, Migeon CJ, Miller WL, Nenadovich TL, Oberfield SE, Pass KA, Poppas DP, Lloyd-Puryear MA, Quigley CA, Riepe FG, Rink RC, Rivkees SA, Sandberg DE, Schaeffer TL, Schlussel RN, Schneck FX, Seely EW, Snyder D, Speiser PW, Therrell BL, Vanryzin C, Vogiatzi MG, Wajnrajch MP, White PC, Zuckerman AE.

Int J Pediatr Endocrinol. 2010;2010:275213. doi: 10.1155/2010/275213. Epub 2011 Jan 10.

45.

What would you do? Should this independent hospital affiliate?

Zuckerman AM.

Healthc Financ Manage. 2010 Dec;64(12):108-10. No abstract available.

PMID:
21265280
46.

Realizing the full financial benefits of true integration.

McCarthy KH, Zuckerman AM.

Healthc Financ Manage. 2010 Nov;64(11):78-82, 84, 86 passim.

PMID:
21061822
47.

J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.

Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators.

Eur Heart J. 2010 Dec;31(23):2897-908. doi: 10.1093/eurheartj/ehq328. Epub 2010 Sep 16.

PMID:
20846991
48.

What would you do? How should this IDS develop and thrive?

Zuckerman A.

Healthc Financ Manage. 2010 Aug;64(8):106-8. No abstract available.

PMID:
20707268
49.

What would you do? Can this large hospital find a partner?

Zuckerman AM.

Healthc Financ Manage. 2010 Jun;64(6):130, 132, 134. No abstract available.

PMID:
20533688
50.

What would you do? Primary care growth at any cost?

Zuckerman AM.

Healthc Financ Manage. 2010 Apr;64(4):112-4. No abstract available.

PMID:
20358884

Supplemental Content

Loading ...
Support Center